InvestorsHub Logo
Followers 32
Posts 19884
Boards Moderated 0
Alias Born 07/10/2015

Re: madg post# 20908

Monday, 11/19/2018 6:00:10 PM

Monday, November 19, 2018 6:00:10 PM

Post# of 40985
Actually there are multiple pieces of evidence to suggest its Zimmer like Zimmer donating its IP for testing, Sonny working for Zimmer for 12+ years, Max Link's connection to Zimmer, & one of Amedicas co-founders being heavily connected to Zimmer. Not to mention that Zimmer needs something new to differentiate itself after Trabecular Metal failed.

As far as commercialization is concerned am I incorrect in assuming that when you submit a product to the FDA the accompanying penultimate study, in this case 12mc study, should contain the the various IP from the study? If so then they cannot commercialize the product without Zimmers involvement.

The flaw in thinking its Confor is the same flaw in me thinking K2M in 2016. Confor is a joint company like k2m is a spine company. Sintx is a material company with many potential products. The R&D agreement is not limited to just joints. Logically the company developing with Sintx must be multi-faceted in orthopedics and be able to commercialize outside of orthopedics now that Si3N4 has so many uses outside of ortho.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SINT News